Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart risks in adrenal tumor patients under the microscope

NCT ID NCT07182175

Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 150 patients with functional adrenal tumors to see how their heart and blood pressure change before and after surgery. Researchers will use heart ultrasounds and blood pressure monitoring to understand recovery and risks. The goal is to help doctors choose better medicines and make safer surgical plans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better manage heart risks and choose safer treatments for patients with adrenal tumors before and after surgery.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients with functional adrenal tumors who are hospitalized and/or seen in the outpatient clinic of the Department of Urology at Peking University First Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed in the Department of Urology, Peking University First Hospital with pheochromocytoma and paraganglioma (PPGL), primary aldosteronism (PA), or Cushing syndrome (CS); * Written informed consent obtained. Exclusion Criteria: * Patients with PPGL, PA, or CS who receive medication or conservative treatment and are not eligible for surgical resection; * Patients with communication disorders or severe physical impairments such as aphasia, or visual/hearing disabilities; * Patients with severe mental illness who cannot cooperate with the study; * Pregnant women or patients otherwise deemed unsuitable for participation by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal gland cancer adrenal gland neoplasm Cushing syndrome hyperaldosteronism paraganglioma pheochromocytoma pheochromocytoma-paraganglioma primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal tumor Cushing's syndrome Pheochromocytoma/paraganglioma (PPGL) Primary aldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.